suffering from emtricitabine and tenofovir Generic Name: emtricitabine and tenofovir (EM trye SYE ta been and ten OF oh vir ) Brand Name: AccessPak for HIV PEP Basic, Descovy, Truvada Overview Side Effects Dosage Professional Interactions More Pregnancy Warnings User Reviews Support Group Q & A What is emtricitabine and tenofovir? Emtricitabine and tenofovir are antiviral medicines that prevent human immunodeficiency virus (HIV) from multiplying in your body. Emtricitabine and tenofovir is a combination medicine used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). This medicine is not a cure for HIV or AIDS, but it can be used to treat HIV in adults and children who are at least 12 years old and weigh at least 17 kilograms (37 pounds). Emtricitabine and tenofovir is also used in children who weigh between 55 and 77 pounds (25 to 35 kilograms) and who take certain other HIV medications. The Truvada brand of this medicine may be used together with safer-sex practices to reduce the risk of becoming infected with HIV. You must be HIV-negative and an adult to use Truvada for this purpose. Truvada may not provide protection from disease in every person. Emtricitabine and tenofovir may also be used for purposes not listed in this medication guide. Slideshow 2016 New Drug Approvals: The Year That Was What is the most important information I should know about emtricitabine and tenofovir? Do not take this combination medicine if you also take other medicines that contain emtricitabine, tenofovir, lamivudine, or adefovir. Emtricitabine and tenofovir is sometimes used to reduce the risk of becoming infected with HIV. You must be HIV-negative and an adult to use the medicine for this purpose. This medicine may cause a serious condition called lactic acidosis. Get emergency medical help if you have even mild symptoms such as: muscle pain or weakness, numb or cold feeling in your arms and legs, trouble breathing, stomach pain, nausea with vomiting, fast or uneven heart rate, dizziness, or feeling very weak or tired. If you have hepatitis B you may develop liver symptoms after you stop taking this medicine, even months after stopping. What should I discuss with my healthcare provider before taking emtricitabine and tenofovir? You should not take this medicine if you are allergic to emtricitabine or tenofovir. Do not take if you also use other medicines that contain emtricitabine, tenofovir, lamivudine, or adefovir (such as Atripla, Combivir, Complera, Descovy, Dutrebis, Emtriva, Epivir, Epzicom, Genvoya, Hepsera, Odefsey, Stribild, Triumeq, Trizivir, or Viread). Do not take Truvada to reduce infection risk if you are HIV-positive, if have been exposed to HIV within the past month, or if you had any symptoms (such as fever, sore throat, night sweats, swollen glands, diarrhea, body aches). If you take Truvada to reduce your risk of HIV infection: You must have a negative HIV test immediately before you start taking the medicine. An HIV test is also required every 3 months during treatment. To make sure this medicine is safe for you, tell your doctor if you have ever had: liver disease (especially hepatitis B); osteopenia (low bone mineral density); or kidney disease. Some people taking this medicine develop a serious condition called lactic acidosis. This may be more likely in women, in people who are overweight or have liver disease, and in people who have taken HIV/AIDS medication for a long time. Talk with your doctor about your risk. HIV can be passed to your baby if you are not properly treated during pregnancy. Take all of your HIV medicines as directed to control your infection. You should not breast-feed while you are using this medication to treat or prevent HIV. Women with HIV or AIDS should not breast-feed a baby. Even if your baby is born without HIV, the virus may be passed to the baby in your breast milk. Emtricitabine and tenofovir is not approved for anyone younger than 12 years old. The child receiving this medicine must weigh at least 37 pounds. How should I take emtricitabine and tenofovir? Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended. You may take this medicine with or without food. Use emtricitabine and tenofovir regularly to get the most benefit. Try not to miss any doses. Get your prescription refilled before you run out of medicine completely. While using this medicine you may need frequent medical tests to check your kidney and liver function, or your bone mineral density. HIV/AIDS is usually treated with a combination of drugs. Use all medications as directed by your doctor. Read the medication guide or patient instructions provided with each medication. Do not change your doses or medication schedule without your doctor's advice. Every person with HIV or AIDS should remain under the care of a doctor. Store in the original container at room temperature, away from moisture and heat. Keep the bottle tightly closed when not in use. If you have hepatitis B you may develop liver symptoms after you stop taking this medication, even months after stopping. Your doctor may want to check your liver function for several months after you stop using emtricitabine and tenofovir. What happens if I miss a dose? Take the missed dose as soon as you remember. Skipping doses may increase the risk of your virus becoming resistant to antiviral medicine. What happens if I overdose? Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. What should I avoid while taking emtricitabine and tenofovir? Taking this medication will not prevent you from passing HIV to other people. Do not have unprotected sex or share razors or toothbrushes. Talk with your doctor about safe ways to prevent HIV transmission during sex. Sharing drug or medicine needles is never safe, even for a healthy person. Emtricitabine and tenofovir side effects Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Early symptoms of lactic acidosis may get worse over time and this condition can be fatal. Get emergency medical help if you have even mild symptoms: muscle pain or weakness, numb or cold feeling in your arms and legs, trouble breathing, stomach pain, nausea with vomiting, irregular heart rate, dizziness, or feeling very weak or tired. Call your doctor at once if you have: sudden or unusual bone pain; kidney problems--little or no urination, painful or difficult urination, swelling in your feet or ankles, feeling tired or short of breath; or liver problems--nausea, swelling around your midsection, upper stomach pain, unusual tiredness, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes). Emtricitabine and tenofovir may increase your risk of certain infections or autoimmune disorders by changing the way your immune system works. Symptoms may occur weeks or months after you start treatment with emtricitabine and tenofovir. Tell your doctor if you have: signs of a new infection--fever, night sweats, swollen glands, mouth sores, diarrhea, stomach pain, weight loss; chest pain (especially when you breathe), dry cough, wheezing, feeling short of breath; cold sores, sores on your genital or anal area; rapid heart rate, feeling anxious or irritable, weakness or prickly feeling, problems with balance or eye movement; trouble speaking or swallowing, severe lower back pain, loss of bladder or bowel control; or swelling in your neck or throat (enlarged thyroid), menstrual changes, impotence, loss of interest in sex. Common side effects may include: headache, dizziness, feeling depressed or tired; sleep problems (insomnia), strange dreams; nausea, stomach pain; weight loss; or rash. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. Side Effects (complete list) Emtricitabine and tenofovir dosing information Usual Adult Dose for HIV Infection: Emtricitabine 200 mg-tenofovir alafenamide 25 mg (1 tablet) orally once a day Emtricitabine 200 mg-tenofovir DF 300 mg (1 tablet) orally once a day Comments: -Patients should be tested for HBV infection before starting this drug. -In all patients, estimated CrCl, urine glucose, and urine protein should be assessed before starting emtricitabine-tenofovir alafenamide and should be monitored during therapy. -Emtricitabine-tenofovir alafenamide is recommended for patients at least 35 kg. -Emtricitabine-tenofovir DF is not recommended as a component of a triple nucleoside regimen; it should not be used with other emtricitabine-containing, tenofovir-containing, or lamivudine-containing products. -Use of emtricitabine-tenofovir DF in therapy-experienced patients should be guided by laboratory testing and treatment history. Use: In combination with other antiretroviral agents, for treatment of HIV-1 infection Usual Adult Dose for Pre-Exposure Prophylaxis: Emtricitabine 200 mg-tenofovir DF 300 mg (1 tablet) orally once a day Comments: -This drug should be used only as part of a comprehensive prevention plan that includes other prevention measures (e.g., safer sex practices); this drug is not always effective in preventing acquisition of HIV-1. -Uninfected individuals should be advised to strictly adhere to the dosing regimen; efficacy of this drug in reducing risk of acquiring HIV-1 strongly correlated with adherence. -The manufacturer product information (and current guidelines) should be consulted for further guidance. Use: In combination with safer sex practices, for preexposure prophylaxis to reduce the risk of sexually acquired HIV-1 in uninfected individuals at high risk Usual Adult Dose for Occupational Exposure: US Public Health Service working group recommendations: Emtricitabine 200 mg-tenofovir DF 300 mg (1 tablet) orally once a day Duration of therapy: 28 days, if tolerated Comments: -This drug plus raltegravir is recommended as the preferred regimen for HIV postexposure prophylaxis; this drug is also recommended as a component in various alternative regimens. -Prophylaxis should be started as soon as possible, preferably within hours after exposure. -The optimal duration of prophylaxis is unknown and may differ based on institution protocol. -Current guidelines should be consulted for additional information. Usual Adult Dose for Nonoccupational Exposure: US CDC recommendations: Emtricitabine 200 mg-tenofovir DF 300 mg (1 tablet) orally once a day Duration of therapy: 28 days Comments: -This drug plus (raltegravir or dolutegravir) is recommended as the preferred regimen for nonoccupational postexposure prophylaxis of HIV infection in adults (including pregnant women) with CrCl at least 60 mL/min; this drug plus darunavir/ritonavir is recommended as an alternative regimen for such patients. If other alternatives are considered, this drug is recommended as a component in various regimens. -Prophylaxis should be started as soon as possible, within 72 hours of exposure. -Current guidelines should be consulted for additional information. Usual Pediatric Dose for HIV Infection: Emtricitabine-tenofovir alafenamide: 12 years or older and at least 35 kg: Emtricitabine 200 mg-tenofovir alafenamide 25 mg (1 tablet) orally once a day Emtricitabine-tenofovir DF: 17 to less than 22 kg: Emtricitabine 100 mg-tenofovir DF 150 mg (1 tablet) orally once a day 22 to less than 28 kg: Emtricitabine 133 mg-tenofovir DF 200 mg (1 tablet) orally once a day 28 to less than 35 kg: Emtricitabine 167 mg-tenofovir DF 250 mg (1 tablet) orally once a day At least 35 kg: Emtricitabine 200 mg-tenofovir DF 300 mg (1 tablet) orally once a day Comments: -Patients should be tested for HBV infection before starting this drug. -In all patients, estimated CrCl, urine glucose, and urine protein should be assessed before starting emtricitabine-tenofovir alafenamide and should be monitored during therapy. -Emtricitabine-tenofovir DF is recommended for pediatric patients who can swallow a whole tablet. -Emtricitabine-tenofovir DF is not recommended as a component of a triple nucleoside regimen; it should not be used with other emtricitabine-containing, tenofovir-containing, or lamivudine-containing products. -Use of emtricitabine-tenofovir DF in therapy-experienced patients should be guided by laboratory testing and treatment history. Use: In combination with other antiretroviral agents, for treatment of HIV-1 infection Usual Pediatric Dose for Nonoccupational Exposure: US CDC recommendations for adolescents 13 years or older: Emtricitabine 200 mg-tenofovir DF 300 mg (1 tablet) orally once a day Duration of therapy: 28 days Comments: -This drug plus (raltegravir or dolutegravir) is recommended as the preferred regimen for nonoccupational postexposure prophylaxis of HIV infection in adolescents with CrCl at least 60 mL/min; this drug plus darunavir/ritonavir is recommended as an alternative regimen for such patients. If other alternatives are considered, this drug is recommended as a component in various regimens. -Prophylaxis should be started as soon as possible, within 72 hours of exposure. -Current guidelines should be consulted for additional information. What other drugs will affect emtricitabine and tenofovir? Tell your doctor about all your current medicines and any you start or stop using, especially: chemotherapy, injected antibiotics, injectable osteoporosis medications, medicine for bowel disorders, medicine to prevent organ transplant rejection; antiviral medicine to treat hepatitis C--ledipasvir, sofosbuvir, velpatasvir; other HIV medications--atazanavir, darunavir, didanosine, lopinavir, ritonavir; or some pain or arthritis medicines--aspirin, Tylenol, Advil, and Aleve. This list is not complete. Other drugs may interact with emtricitabine and tenofovir, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide. Next Side Effects Print this page Add to My Med List More about emtricitabine/tenofovir Side Effects During Pregnancy Dosage Information Drug Interactions Support Group 16 Reviews Add your own review/rating Drug class: antiviral combinations Consumer resources Emtricitabine and Tenofovir Disoproxil Fumarate Emtricitabine and tenofovir (Advanced Reading) Other brands: Truvada , AccessPak for HIV PEP Basic Professional resources Emtricitabine and Tenofovir Disoproxil Fumarate (Wolters Kluwer) Related treatment guides HIV Infection Nonoccupational Exposure Occupational Exposure Pre-Exposure Prophylaxis Where can I get more information? Your pharmacist can provide more information about emtricitabine and tenofovir. Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed. Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist. Copyright 1996-2012 Cerner Multum, Inc. Version: 11.01. Date modified: December 03, 2017 Last reviewed: October 25, 2017} Drug Status Rx Availability Prescription only B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class Antiviral combinations Related Drugs Pre-Exposure Prophylaxis Truvada , emtricitabine / tenofovir , AccessPak for HIV PEP Basic , More... HIV Infection Truvada , Atripla , Norvir , Viread , Isentress , Prezista , More... Occupational Exposure Truvada , Atripla , Viread , Isentress , lamivudine , abacavir , More... Nonoccupational Exposure Truvada , Atripla , Viread , lamivudine , abacavir , tenofovir , More... Emtricitabine / tenofovir Rating 16 User Reviews 9.0 /10 16 User Reviews 9.0 Rate it! Help and Support Looking for answers? Ask a question or go join the emtricitabine / tenofovir support group to connect with others who have similar interests.} } understand that
tremendous emtricitabine and tenofovir 46
EmoticonEmoticon